Prime Highlights
- Mazzanti is among the youngest managers in Italy to lead a major pharmaceutical company, with expertise in oncology and market access.
- Accord Healthcare Italia is expanding beyond generics into specialty therapies, biosimilars, and innovative drug formulations.
Key Facts
- Accord Healthcare Italia is a pharmaceutical company specialising in generic drugs, now expanding into oncology and specialty therapies.
- Mazzanti joined Accord Healthcare Italia in March as Commercial Director before being elevated to Country Director.
Background
Nicola Mazzanti has also been appointed the new Country Director of Accord Healthcare Italia, and this is a major move towards the company repositioning its strategies in the Italian pharmaceutical market.
Mazzanti has a good background in health economics, business strategy and market access. He has worked in commercial and market access functions in both domestic and international markets, specializing in oncology, rare diseases and innovative therapies. He came to Accord Healthcare Italia in March as Commercial Director with responsibility to market and sell, assess the market and tenders before assuming his present position.
At 260 words, Mazzanti is among the youngest managers in Italy to lead a major company in the pharmaceutical sector. His academic background includes an Executive MBA at SDA Bocconi, Milan, and a specialisation in Health Economics and Management from the University of Bologna and Oslo.
Mazzanti stated that Accord Healthcare Italia is a dynamic and fast-growing company that aligns with his values of accessible healthcare and responsible innovation, adding that the team will work to strengthen the company’s presence and expand its offerings of generics, biosimilars, and value-added drugs, with the patient at the centre.
Accord Healthcare Italia, traditionally known for generic drugs, is now expanding into specialty therapies. The company is enhancing its oncology emphasis, which includes small-cell lung cancer, prostate cancer, bladder cancer, and osteoporosis. It is also diversifying its portfolio by adding new chemical entities, biologics and value-added formulations.
The company is still developing an operating model that is flexible and combines direct affiliates and distribution partnerships to achieve quicker and more sustainable access to therapies in various markets.
